Vyriad officials say that the company's G-Link platform can address some of the most persistent challenges in in vivo delivery.

New solutions include customized reagents that scale from bench to clinical trials, industrialized lentiviral vector manufacturing techniques, and innovations to boost lentiviral transduction.

Chemotherapy kills cancer cells, but it also leaves behind something troubling: damaged cells that stop dividing yet refuse to die. These senescent cells, sometimes called “zombie” cells, linger in ...

CAR T-cell therapy has been hugely successful in treating certain types of tumours, and stiffening up cancer cells beforehand ...

The University of Texas MD Anderson Cancer Center and CTMC, a joint venture between UT MD Anderson and Resilience, today ...

University of Barcelona develops ARI-0001, a not-for-profit CAR-T therapy using EU hospital exemption rules to improve ...

Presented improved editing data in non-human primates (NHP) for sickle cell disease (SCD), demonstrating a single dose of Gene Writer achieved an ...

During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

In this retrospective analysis, researchers used real-world data to investigate sex-associated differences in CAR T-cell therapy-related toxicity.

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy. Kelonia is a lentiviral ...